HK1160779A1 - Cdk inhibitor for the treatment of mesothelioma - Google Patents

Cdk inhibitor for the treatment of mesothelioma

Info

Publication number
HK1160779A1
HK1160779A1 HK12101219.9A HK12101219A HK1160779A1 HK 1160779 A1 HK1160779 A1 HK 1160779A1 HK 12101219 A HK12101219 A HK 12101219A HK 1160779 A1 HK1160779 A1 HK 1160779A1
Authority
HK
Hong Kong
Prior art keywords
mesothelioma
treatment
cdk inhibitor
cytotoxic
compound
Prior art date
Application number
HK12101219.9A
Other languages
English (en)
Inventor
Marina Ciomei
Angela Scaburri
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1160779A1 publication Critical patent/HK1160779A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HK12101219.9A 2008-11-24 2012-02-08 Cdk inhibitor for the treatment of mesothelioma HK1160779A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169790 2008-11-24
PCT/EP2009/065643 WO2010058006A1 (en) 2008-11-24 2009-11-23 Cdk inhibitor for the treatment of mesothelioma

Publications (1)

Publication Number Publication Date
HK1160779A1 true HK1160779A1 (en) 2012-08-17

Family

ID=41571035

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101219.9A HK1160779A1 (en) 2008-11-24 2012-02-08 Cdk inhibitor for the treatment of mesothelioma

Country Status (6)

Country Link
US (1) US8912194B2 (xx)
EP (1) EP2376084B1 (xx)
JP (1) JP2012509859A (xx)
CN (1) CN102223885B (xx)
HK (1) HK1160779A1 (xx)
WO (1) WO2010058006A1 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532732T3 (es) * 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
US8586598B2 (en) * 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
EP2668188B1 (en) * 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
EA201491732A1 (ru) * 2012-03-21 2015-08-31 Байер Интеллектуэль Проперти Гмбх Применение (rs)-s-циклопропил-s-(4-{[4-{[(1r,2r)-2-гидрокси-1-метилпропил]окси}-5-(трифторметил)пиримидин-2-ил]амино}фенил)сульфоксимида для лечения специфических опухолей
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
MA44612A (fr) 2016-04-04 2019-02-13 Loxo Oncology Inc Méthodes de traitement de cancers pédiatriques
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
JP2022500388A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
JP7464977B2 (ja) 2020-06-10 2024-04-10 国立大学法人東京農工大学 イヌ中皮腫細胞株

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949558B2 (en) * 2001-11-07 2005-09-27 Yale University Enhancement of taxane-based chemotherapy by a CDK1 antagonist
MXPA05004920A (es) * 2002-11-06 2005-08-18 Cyclacel Ltd Combinacion que comprende un inhibidor cdk y cisplatin.
GEP20094664B (en) 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP2298291A3 (en) 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
US8084027B2 (en) * 2006-02-10 2011-12-27 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
US8518930B2 (en) * 2008-07-29 2013-08-27 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
ES2532732T3 (es) * 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma

Also Published As

Publication number Publication date
WO2010058006A1 (en) 2010-05-27
JP2012509859A (ja) 2012-04-26
US20110224222A1 (en) 2011-09-15
CN102223885B (zh) 2013-04-03
US8912194B2 (en) 2014-12-16
EP2376084B1 (en) 2013-07-17
CN102223885A (zh) 2011-10-19
EP2376084A1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
HK1160779A1 (en) Cdk inhibitor for the treatment of mesothelioma
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
UA106748C2 (xx) Похідні проліну як інгібітори катепсину
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TN2010000203A1 (en) Beta-lactamase inhibitors
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
IN2012DN01233A (xx)
UA99284C2 (xx) ІНГІБІТОРИ р70 S6-КІНАЗИ$ИНГИБИТОРЫ р70 S6-КИНАЗЫ
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MY148723A (en) Use of pinolenic acid for the treatment of obesity
TN2011000298A1 (en) Compounds useful for inhibiting chk1
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2009011843A (es) Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
TW200734334A (en) Treatment of substance abuse
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases